2011 Fiscal Year Final Research Report
The prediction to overcome the drug resistance in pancreatic cancers by proteomics and metaboromics.
| Project/Area Number |
21591766
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OOTSUKA Hideo 東北大学, 病院, 講師 (50451563)
OTSUKI Sumio 熊本大学, 生命科学研究部, 教授 (60323036)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | 膵臓外科学 / 膵癌 / 抗癌剤 / プロテオミクス / メタボロミクス |
|---|
| Research Abstract |
To clarify the resistant mechanism of gemcitabine(GEM), which is a standard agent for pancreatic cancer, a combination of targeted proteomic (LC-MS/MS)and metabolomic analyses were applied. The Attenuation of GEM phosphorylation by suppression of deoxycitidine kinase (dCK)was the most important mechanism for GEM resistance by using acquired resistant model and comparison of tissue expression profile and survival.
|
